Table 3 Baseline characteristics, COPD severity, and prescribed maintenance medications by residential area and by hospital tier

Severity of Airflow Limitation (GOLD stage), n/N (%)

 I

294/2524 (11.6)

163/1988 (8.2)

270/2337 (11.6)

188/2181 (8.6)

 II

1127/2524 (44.7)

756/1988 (38.0)

1028/2337 (44.0)

858/2181 (39.3)

 III

805/2524 (31.9)

751/1988 (37.8)

753/2337 (32.2)

805/2181 (36.9)

 IV

298/2524 (11.8)

318/1988 (16.0)

286/2337 (12.2)

330/2181 (15.1)

GOLD 2016, n/N (%)

 A

397/2585 (15.4)

138/2108 (6.5)

395/2413 (16.4)

141/2286 (6.2)

 B

602/2585 (23.3)

431/2108 (20.4)

603/2413 (25.0)

431/2286 (18.9)

 C

338/2585 (13.1)

225/2108 (10.7)

299/2413 (12.4)

264/2286 (11.5)

 D

1248/2585 (48.3)

1314/2108 (62.3)

1116/2413 (46.2)

1450/2286 (63.4)

GOLD 2017, n/N (%)

 A

574/2733 (21.0)

243/2237 (10.9)

602/2595 (23.2)

216/2381 (9.1)

 B

1129/2733 (41.3)

951/2237 (42.5)

1173/2595 (45.2)

910/2381 (38.2)

 C

212/2733 (7.8)

151/2237 (6.8)

155/2595 (6.0)

208/2381 (8.7)

 D

818/2733 (29.9)

892/2237 (39.9)

665/2595 (25.6)

1047/2381 (44.0)

COPD-Q score,^a mean (SD)

5.9 (2.1)

6.0 (2.0)

5.8 (2.1)

6.1 (1.9)

Prescribed mono- or combination therapy maintenance therapies for COPD, n/N (%)

 ICS

3/2735 (0.1)

2/2237 (0.1)

2/2597 (0.1)

3/2381 (0.1)

 LABA

22/2735 (0.8)

9/2237 (0.4)

9/2597 (0.3)

22/2381 (0.9)

 ICS/LABA

619/2735 (22.6)

696/2237 (31.1)

682/2597 (26.3)

634/2381 (26.6)

 SABA

34/2735 (1.2)

68/2237 (3.0)

11/2597 (0.4)

91/2381 (3.8)

 SAMA

13/2735 (0.5)

14/2237 (0.6)

6/2597 (0.2)

21/2381 (0.9)

 SABA/SAMA

1/2735 (0.0)

1/2237 (0.0)

2/2597 (0.1)

0

 LAMA

500/2735 (18.3)

252/2237 (11.3)

479/2597 (18.4)

275/2381 (11.5)

 ICS/LABA + LAMA

533/2735 (19.5)

336/2237 (15.0)

604/2597 (23.3)

267/2381 (11.2)

 Methylxanthines

71/2735 (2.6)

133/2237 (5.9)

33/2597 (1.3)

171/2381 (7.2)

 TCM

38/2735 (1.4)

42/2237 (1.9)

23/2597 (0.9)

57/2381 (2.4)